Yang, Huiqin; Craig, Dawn; Epstein, David; Bojke, Laura; … - In: PharmacoEconomics 30 (2012) 4, pp. 257-270
-to-head. To compare the effectiveness of the biologics etanercept, infliximab, adalimumab and golimumab, the manufacturer … most cost-effective alternative (etanercept). Despite the manufacturer's claim that golimumab was a cost … biologics were considered equally effective, then etanercept, adalimumab and golimumab had almost equal costs and equal QALYs …